28 August 2020

Contents

Editorial

• HTB: no. 10 – HIV and COVID-19: issue 7 (28 August 2020)

Conference reports

• 23rd International AIDS Conference (AIDS 2020): second reports

• Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing

• Weight gain with integrase inhibitors and TAF: three reports from AIDS 2020

• Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain

• Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study

• Paediatric dolutegravir dosing at AIDS 2020

• COVID-19 outcomes in HIV positive people in two large US cohorts

• AIDS 2020: virtual content now available free and on-demand

• Pathways to an HIV cure: online presentations

Antiretrovirals

• US FDA approves dolutegravir/lamivudine (Dovato) as switch option

• EMA extends indication for darunavir/r to include adolescents >12 years

• ViiV resubmits cabotegravir plus rilpivirine long-acting injections (Cabenuva, Vocabria) to FDA for approval

HIV prevention and transmission

• EMA supports use of dapivirine vaginal ring to prevent HIV in high-incidence countries

Other news

• HIV organisations challenge government proposal to abolish Public Health England

On the web

• Modern ART – community video

• AVAC web interviews about new treatments to prevent HIV

COVID-19: HIV and COVID-19 coinfection

• HIV associated with worse outcomes from COVID-19 in UK ISARIC and OpenSAFELY databases

• European and UK doctors review latest studies on HIV and COVID-19 coinfection

COVID-19: vaccine research

• US activists ensure people living with HIV can enrol in COVID-19 vaccine studies

• HIV organisations oppose active-challenge COVID-19 vaccine studies

• AVAC webinar with Barney Graham: COVID-19 vaccine targets, timelines, efficacy and ethical issues

• Equitable access to vaccines against COVID-19

COVID-19: investigational drugs

• Tocilizumab associated with better outcomes from COVID-19 in US study

• Famotidine associated with better outcomes from COVID-19

• INSIGHT network to study monoclonal antibodies for COVID-19 including LY-CoV555

PDFs

• HTB no 10 – plus: HIV and COVID-19 bulletin no 7 (28 August 2020)